Cell Line Development Market - Forecasts from 2019 to 2024
The global cell line development market is expected to reach US$4.718 billion by 2024 from US$2.122 billion in 2018 growing at a CAGR of 14.24%. A cell line is a permanently established cell culture that will proliferate indefinitely given appropriate fresh medium and space and are often used in place of primary cells to study biological processes. Cell line development refers to the process of developing stable cell lines for the use in in a number of important applications including biologics (e.g. recombinant protein and monoclonal antibody) production, drug screening, and gene functional studies. The process of cell line development include transfection and selection and single cell cloning. The market is expected to show a significant growth during the given forecast period owing to the rise in development and demand for monoclonal antibodies around the globe. Rise in vaccine production and technological innovations in cell line development will also augment the growth of the cell line development market. However, strict regulatory framework coupled with the time consuming process for the development of stable lines might restrain the growth of the market during the given time frame.
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Cell Line Development market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Cell Line Development market.
Major industry players profiled as part of the report are MabPlex Inc. , ATUM, and Selexis among others.
Segmentation
By Type
Recombinant Cell Lines
Hybridomas
Continuous Cell Lines
Primary Cell Lines
By Source
Mammalian Cell Line Development
Non Mammalian Cell Line Development
By Application
Drug Discovery and Research
Bioproduction
Tissue Engineering & Regenerative Medicine
Toxicity Testing
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Cell Line Development market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Cell Line Development market.
Major industry players profiled as part of the report are MabPlex Inc. , ATUM, and Selexis among others.
Segmentation
By Type
Recombinant Cell Lines
Hybridomas
Continuous Cell Lines
Primary Cell Lines
By Source
Mammalian Cell Line Development
Non Mammalian Cell Line Development
By Application
Drug Discovery and Research
Bioproduction
Tissue Engineering & Regenerative Medicine
Toxicity Testing
By Geography
North America
United States
Canada
Others
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Others
Middle East and Africa
Saudi Arabia
UAE
Israel
Others
Asia Pacific
China
India
Australia
South Korea
Others
1. INTRODUCTION
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY TYPE
5.1. Recombinant Cell Lines
5.2. Hybridomas
5.3. Continuous Cell Lines
5.4. Primary Cell Lines
6. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY SOURCE
6.1. Mammalian Cell Line Development
6.2. Non Mammalian Cell Line Development
7. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY GEOGRAPHY
7.1. North America
7.1.1. The U.S
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. U.K.
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. UAE
7.4.3. Israel
7.4.4. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. India
7.5.3. Australia
7.5.4. South Korea
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. COMPANY PROFILES
9.1. Lonza
9.2. Biofactura
9.3. WuXi AppTec
9.4. KBI Biopharma
9.5. ATUM
9.6. Fusion Antibodies plc
9.7. Selexis
9.8. In Vivo
9.9. Celonic AG
9.10. MabPlex Inc.
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
2.3. Validation
3. KEY FINDINGS OF THE STUDY
4. MARKET DYNAMICS
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis
5. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY TYPE
5.1. Recombinant Cell Lines
5.2. Hybridomas
5.3. Continuous Cell Lines
5.4. Primary Cell Lines
6. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY SOURCE
6.1. Mammalian Cell Line Development
6.2. Non Mammalian Cell Line Development
7. GLOBAL CELL LINE DEVELOPMENT MARKET FORECAST BY GEOGRAPHY
7.1. North America
7.1.1. The U.S
7.1.2. Canada
7.1.3. Mexico
7.1.4. Others
7.2. South America
7.2.1. Brazil
7.2.2. Argentina
7.2.3. Others
7.3. Europe
7.3.1. U.K.
7.3.2. France
7.3.3. Germany
7.3.4. Italy
7.3.5. Others
7.4. Middle East and Africa
7.4.1. Saudi Arabia
7.4.2. UAE
7.4.3. Israel
7.4.4. Others
7.5. Asia Pacific
7.5.1. China
7.5.2. India
7.5.3. Australia
7.5.4. South Korea
7.5.5. Others
8. COMPETITIVE INTELLIGENCE
8.1. Competition and Offerings Analysis of Key Vendors
8.2. Strategies of Key Players
8.3. Recent Investments and Deals
9. COMPANY PROFILES
9.1. Lonza
9.2. Biofactura
9.3. WuXi AppTec
9.4. KBI Biopharma
9.5. ATUM
9.6. Fusion Antibodies plc
9.7. Selexis
9.8. In Vivo
9.9. Celonic AG
9.10. MabPlex Inc.
